What is MOTS-c and why does its structure influence price?
MOTS-c (mitochondrial open-reading-frame of the twelve-S rRNA-c) is a short mitochondrial-derived peptide of 16 residues, encoded within the mitochondrial 12S rRNA region and studied extensively as a signalling molecule in metabolic and stress-response research (PMID:25738459; PMID:36761202). Its relatively short sequence makes it more tractable to synthesise than large peptides, but sequence-specific features still shape manufacturing cost. Residues prone to on-resin side reactions, difficult coupling steps and the risk of deletion or truncation impurities all determine how many purification passes are required to reach a target purity, and each pass consumes material and analytical time. The peptide has also been reported to translocate to the nucleus under metabolic stress, a mechanistic detail relevant to why researchers characterise it carefully rather than assume identity from a label (PMID:29983246). From a procurement standpoint, structure matters because two vials advertised as 'MOTS-c' can differ in the proportion of correct full-length sequence versus related substances. A supplier that invests in orthogonal identity confirmation and impurity profiling incurs cost that appears in the price. Understanding the molecule — its length, composition and the impurities its synthesis tends to generate — lets a buyer read a certificate of analysis critically and judge whether a low price reflects efficiency or an absence of the analytical work that defines research-grade material. Reviews summarising MOTS-c biology and its position among mitochondrial-derived peptides provide useful context for why identity rigour is emphasised (PMID:36233287; PMID:36670507).
How does chromatographic purity grade change the per-mg cost?
The single largest driver of MOTS-c price is the purity grade demonstrated by reversed-phase HPLC (RP-HPLC). Purity is typically reported as the percentage of total integrated peak area attributable to the main peak at a defined detection wavelength, with related substances quantified as individual and total impurities. Moving from, say, a lower purity specification to a higher one is not linear in cost: each incremental percentage point near the top of the scale demands additional preparative chromatography, tighter fraction collection and greater yield loss, so material that clears a stringent specification is inherently more expensive per milligram. When comparing Australian quotes, the purity figure is only meaningful alongside the method: gradient conditions, column chemistry, wavelength and whether peak purity was assessed for co-elution using diode-array detection. A stated purity without an accompanying chromatogram and method summary is difficult to verify. Buyers should also confirm whether the quoted purity is HPLC area percent or a net-content-adjusted figure, because these describe different things. A legitimate specification pairs the purity claim with acceptance criteria — the limits the batch had to meet to be released — so the number is anchored rather than aspirational. Two suppliers can both print '>98%' yet apply different integration thresholds and system-suitability requirements, producing genuinely different material. This is why price comparison should always be normalised to comparable analytical rigour rather than the headline percentage alone. When a lower price accompanies vague or missing chromatographic evidence, the apparent saving may reflect a less rigorous purification and characterisation workflow rather than true value for the research use intended.
Why do net peptide content and counterion analysis affect the mass you receive?
A vial labelled '10 mg MOTS-c' does not necessarily contain 10 mg of peptide. Lyophilised synthetic peptides are salts, and a substantial fraction of the gross weight can be counterions — commonly trifluoroacetate (TFA) from purification or acetate after exchange — plus residual water and bound solvent. Net peptide content is the proportion of the gross mass that is actually peptide backbone, and it is determined by techniques such as amino acid analysis, with water contributing separately via Karl Fischer titration. Two vials at the same gross weight and the same HPLC purity can differ materially in the milligrams of peptide they deliver once counterion and moisture are subtracted. This directly affects true cost per milligram of peptide. Counterion identity also matters analytically: TFA can interfere with certain downstream applications, so some workflows specify acetate salts, and counterion quantification documents which form a batch contains. A transparent supplier reports net peptide content, water content and counterion so a buyer can convert a quoted price into a cost per milligram of actual peptide rather than per milligram of powder. When you request MOTS-c pricing in Australia, ask whether the figure is per gross milligram or adjusted for net content — the two can diverge considerably. Documentation of these parameters is part of what separates characterised research material from an undocumented powder, and the analytical labour behind amino acid analysis, Karl Fischer and counterion determination is a real, defensible component of price.
What identity and impurity documentation should back an Australian MOTS-c price?
Price without documentation is difficult to evaluate, so a defensible MOTS-c quote should be supported by a certificate of analysis (CoA) and, ideally, the raw analytical evidence behind it. Identity is confirmed by mass spectrometry — electrospray ionisation (ESI-MS) or MALDI-TOF — matching the observed molecular mass to the theoretical mass of the 16-residue sequence, with tandem MS able to map the sequence via fragment ions for deeper confirmation. Because MOTS-c is often studied for its intracellular and nuclear signalling behaviour under stress, researchers need confidence that the material is the correct molecule and not a mislabelled or degraded analogue (PMID:29983246; PMID:34798268). Impurity documentation should quantify related substances: truncated and deletion sequences, oxidation and deamidation products, and aggregates where relevant. Orthogonal methods — pairing RP-HPLC with an independent MS-based purity check — reduce the risk that a single method masks a co-eluting impurity. A complete documentation pack typically includes the HPLC chromatogram with integration, the mass spectrum with assigned masses, net peptide content, water content, counterion identity and the batch or lot number for traceability. For laboratories placing repeat or bulk orders, per-lot documentation and lot-to-lot consistency data are especially valuable, because they let a group correlate experimental variability with characterised material rather than unknown inputs. When comparing Australian suppliers, weigh the price against how much of this evidence is supplied by default versus withheld or available only on request. The breadth of MOTS-c research — spanning metabolic, cardiovascular and ageing models (PMID:36156853; PMID:34859377; PMID:31293078) — reinforces why documented identity and purity underpin any credible price.
How do batch size, local Australian stock and dispatch affect value?
Beyond the chemistry of a single vial, procurement structure shapes the effective price of MOTS-c in Australia. Synthesis and analytical release testing carry fixed costs that are amortised across a batch, so larger lots generally lower per-milligram cost — provided the buyer still receives per-vial traceability to the parent lot rather than a diluted documentation trail. Bulk and multi-vial orders can therefore represent value when a consolidated batch report covers every vial and cross-references each to the same CoA. Local Australian stock is a distinct value factor: material already held domestically avoids international transit variables and can be dispatched with tracked delivery and batch documentation included, so the price reflects a characterised, in-country product rather than an unverified import. Note that this is about local availability, tracked dispatch and paperwork continuity — not any temperature-controlled or refrigerated shipping service. When evaluating a quote, consider the total delivered value: the per-milligram cost adjusted for net peptide content, the completeness of the analytical package, the lot traceability, and whether the supplier provides consistent documentation across repeat orders so results remain comparable over time. A slightly higher headline price accompanied by full RP-HPLC and MS documentation, net-content adjustment and per-lot traceability can be more economical for a research programme than a cheaper, undocumented alternative that forces in-house re-characterisation. For programmes running longitudinal or replicate work, lot consistency is itself a form of value because it reduces a variable that would otherwise confound interpretation. Framing price this way — cost per characterised milligram, delivered with documentation — is the most defensible basis for comparing Australian MOTS-c suppliers on strictly analytical, research-only grounds.
Order Mots C with documentation
If this guide helped you evaluate Mots C for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Mots C card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Why does MOTS-c price vary so much between Australian suppliers?
Variation reflects purity grade, net peptide content, counterion and moisture burden, batch size and documentation depth. A low price may indicate less preparative purification or missing analytical evidence, while a higher price often includes full RP-HPLC, mass spectrometry and net-content data. Normalise quotes to cost per characterised milligram before comparing.
Does a 10 mg MOTS-c vial contain 10 mg of peptide?
Not necessarily. Lyophilised peptides are salts, so gross weight includes counterions such as trifluoroacetate or acetate plus residual water. Net peptide content, measured by amino acid analysis with water assessed by Karl Fischer, reveals how many milligrams are actual peptide, which affects true cost per milligram.
What documentation should accompany a research-grade MOTS-c price?
A certificate of analysis with RP-HPLC purity and chromatogram, mass spectrometry identity confirmation, net peptide content, water content, counterion identity and a batch or lot number for traceability. Orthogonal HPLC and MS purity checks add confidence that no co-eluting impurity is masked.
How is MOTS-c identity confirmed analytically?
Identity is confirmed by mass spectrometry — ESI-MS or MALDI-TOF — matching the observed mass to the theoretical mass of the 16-residue sequence. Tandem MS can map the sequence through fragment ions, providing deeper confirmation that the material is the intended molecule rather than a mislabelled or degraded analogue.
Does bulk ordering lower the effective MOTS-c price?
Often, yes, because fixed synthesis and release-testing costs are amortised across a larger lot. Value depends on retaining per-vial traceability to the parent batch and a consolidated documentation package, so each vial remains cross-referenced to the same certificate of analysis for consistent research use.
References
- PMID:25738459 — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Cell Metab — 2015
- PMID:36761202 — MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne) — 2023
- PMID:29983246 — The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress — Cell Metab — 2018
- PMID:36233287 — MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases — Int J Mol Sci — 2022
- PMID:36670507 — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging — J Transl Med — 2023
- PMID:34798268 — The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus — Pharmacol Res — 2022
- PMID:36156853 — Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice — J Cell Mol Med — 2022
- PMID:34859377 — The Mitochondrial-Derived Peptide MOTS-c Attenuates Oxidative Stress Injury and the Inflammatory Response of H9c2 Cells Through the Nrf2/ARE and NF-κB Pathways — Cardiovasc Eng Technol — 2022
- PMID:31293078 — The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity — Physiol Rep — 2019
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
